Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flurbiprofen cataplasm in knee osteoarthritis: randomized, single-blind, positive-drug/placebo-controlled, multicenter trial
CTR20243234Phase 3Completed
- Sponsor
- Baidai Pharmaceutical
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of flurbiprofen in knee osteoarthritis (OA), adhesive capsulitis (AC), tendinitis, tendovaginitis, Lateral Epicondylitis (LET), sponsored by Baidai Pharmaceutical. Started Aug 2024; status: completed.
02
Drugs
flurbiprofen
03
Conditions
knee osteoarthritis (OA)adhesive capsulitis (AC)tendinitistendovaginitisLateral Epicondylitis (LET)
Beyond the preview
Go deeper on CTR20243234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243234.